| Bioactivity | DTX-P7 is a peptide-drug conjugate. DTX-P7, composed of Docetaxel (DTX, HY-B0011) and a heptapeptide (P7), induces unfolded protein response and subsequent apoptosis by degrading Hsp90[1]. |
| Invitro | DTX-P7 以剂量和时间依赖的方式抑制膜上 Hsp90 的表达，而mRNA水平没有观察到变化[1]。DTX-P7 增强了PERK 和 eIF2α 的磷酸化，但在 A549 细胞暴露时没有观察到 XBP-1 mRNA 剪接[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> DTX-P7 相关抗体: |
| In Vivo | DTX-P7 (mice implanted with A549 xenograft tumor, 15/30 mg/kg, once a week for 4 weeks) 通过降解 DYRK1A 并随后使细胞周期重新进入，抑制了休眠/缓慢增殖的 A549/CD133 + 细胞的肿瘤生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| Formula | C84H118N8O25 |
| Molar Mass | 1639.87 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yao Jiang, et al. DTX-P7, a peptide-drug conjugate, is highly effective for non-small cell lung cancer. J Hematol Oncol. 2022 Jun 3;15(1):73. |